Is ALT a marker of hepatocellular injury that is commonly elevated in MASLD?

Alanine aminotransferase (ALT) is an enzyme primarily found in the cytoplasm of hepatocytes, making it a highly specific biomarker for liver health. In metabolic-associated steatotic liver disease (MASLD), chronic liver fat accumulation triggers metabolic stress, often leading to detectable elevations in this enzyme as liver cells undergo various forms of injury.

Clinical and diagnostic evidence

ALT elevation is a hallmark finding in the clinical management of MASLD, although it is not present in every case.

• Prevalence: Research indicates that ALT elevation (often defined as >1.5x the upper limit of normal) occurs in approximately 47% to 58% of patients with metabolic risk factors such as type 2 diabetes or obesity.
• Screening Utility: In general population studies, ALT-defined steatotic liver disease prevalence ranges from 34.5% to 43%. While ALT can remain within the "normal" range in some individuals with MASLD, it serves as the primary case-finding tool for identifying at-risk adults.
• Specificity: ALT is significantly more liver-specific than aspartate aminotransferase (AST) because it lacks substantial extrahepatic sources like muscle or heart tissue. In clinical practice, levels exceeding 3x the upper limit of normal typically signify significant hepatocellular injury.

Mechanistic explanations

The presence of ALT in the blood is a direct consequence of hepatocyte membrane instability rather than active secretion.

• Membrane Leakage: In MASLD, the accumulation of triglycerides leads to lipotoxicity and oxidative stress. This process causes lipid peroxidation and inflammation-induced membrane blebbing, which allows the "leakiness" of the hepatocyte plasma membrane and the passive efflux of ALT into the systemic circulation.
• Necrosis vs. Apoptosis: The most dramatic elevations in ALT (sometimes >1000 IU/L in acute injury) result from necrosis, where massive membrane rupture releases 80-90% of the cell's cytoplasmic ALT. Conversely, because apoptotic cell death sequesters cellular contents within intact bodies, it typically does not result in significant ALT release until secondary necrosis occurs.

Bottom line

• ALT is a robust and specific indicator of hepatocellular injury caused by membrane disruption. In MASLD, it is a common biomarker that signals lipotoxicity and increased risk for advanced fibrosis, though it must be interpreted alongside metabolic risk factors as some patients may maintain normal levels despite underlying liver fat.